Top Page
Mesoblast Limited
(Sydney:MSB)
Mesoblast Limited (MSB) vs. iShares MSCI Australia ETF (EWA)
Mesoblast Limited Business Overview & Revenue Model
Mesoblast Limited Earnings Call Summary
Mesoblast Limited Financial Statement Overview
| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.67M | 5.90M | 7.50M | 10.21M | 7.46M | 32.16M |
| Gross Profit | -22.57M | -35.17M | -47.42M | -53.36M | -78.28M | -49.34M |
| EBITDA | -49.42M | -56.08M | -58.55M | -76.57M | -107.60M | -75.41M |
| Net Income | -103.35M | -87.96M | -81.89M | -91.35M | -98.81M | -77.94M |
Balance Sheet | ||||||
| Total Assets | 653.32M | 669.15M | 669.41M | 662.14M | 744.72M | 733.60M |
| Cash, Cash Equivalents and Short-Term Investments | 38.03M | 62.56M | 70.92M | 60.03M | 136.88M | 129.33M |
| Total Debt | 126.11M | 118.92M | 116.50M | 106.91M | 105.50M | 99.31M |
| Total Liabilities | 192.06M | 188.80M | 167.58M | 165.10M | 163.32M | 184.28M |
| Stockholders Equity | 461.26M | 480.36M | 501.84M | 497.04M | 581.40M | 549.33M |
Cash Flow | ||||||
| Free Cash Flow | -21.07M | -48.79M | -63.58M | -66.01M | -108.33M | -58.61M |
| Operating Cash Flow | -20.66M | -48.46M | -63.27M | -65.78M | -106.68M | -56.37M |
| Investing Cash Flow | 327.50K | -97.00K | -194.00K | -232.00K | -1.65M | -3.27M |
| Financing Cash Flow | 4.58M | 40.25M | 74.50M | -9.87M | 114.47M | 137.04M |
Mesoblast Limited Technical Analysis
Mesoblast Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $1.81B | 13.12 | 51.39% | ― | -8.06% | -10.13% | |
77 Outperform | AU$539.83M | 13.91 | 19.93% | 0.46% | 12.74% | 27.56% | |
56 Neutral | AU$33.82M | ― | -36.95% | ― | ― | 11.11% | |
52 Neutral | $7.39B | >-0.01 | -63.86% | 2.36% | 16.15% | 0.36% | |
50 Neutral | AU$350.49M | ― | -31.16% | ― | ― | 14.47% | |
49 Neutral | AU$303.55M | ― | -29.77% | ― | 6.07% | 59.09% | |
43 Neutral | $2.14B | ― | -21.31% | ― | ― | ― |
Mesoblast Limited Corporate Events
Mesoblast Limited announced the cessation of 483,254 securities due to the lapse of conditional rights, as the conditions for these securities were not met or became incapable of being satisfied. This announcement may impact the company’s capital structure and could influence investor perceptions regarding the company’s operational and financial strategies.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$1.10 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
Mesoblast Limited has announced the application for the quotation of 2,185,000 ordinary fully paid securities on the Australian Securities Exchange (ASX). This move is part of an employee incentive scheme and reflects the company’s ongoing efforts to enhance its market presence and operational capabilities.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$1.10 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
Mesoblast Limited, a company in the biotechnology sector, has announced that JPMorgan Chase & Co. and its affiliates have ceased to be substantial holders of its voting securities. This change involves various transactions and securities lending agreements handled by JPMorgan’s subsidiaries, impacting a significant number of ordinary shares. The cessation of JPMorgan as a substantial holder may influence Mesoblast’s shareholder dynamics and market perception.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$1.10 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
JPMorgan Chase & Co. and its affiliates have become a substantial holder in Mesoblast Limited, acquiring a 5.35% voting power in the company as of July 2, 2025. This acquisition involves various subsidiaries of JPMorgan holding significant numbers of ordinary shares through different capacities such as securities lending and proprietary trading, potentially impacting Mesoblast’s shareholder structure and market dynamics.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$1.10 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
Mesoblast Limited has aligned with the FDA on key requirements for filing a Biologics License Application for Revascor, a treatment for ischemic heart failure with reduced ejection fraction. This alignment follows a successful Type B meeting, and the company plans to file for accelerated approval by the end of the year, potentially strengthening its position in the regenerative medicine market and providing new treatment options for patients with severe heart conditions.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$1.10 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
JPMorgan Chase & Co. and its affiliates have ceased to be substantial holders in Mesoblast Limited, a company involved in the biopharmaceutical industry. This change in holding reflects a series of transactions involving the purchase, sale, and lending of securities, which resulted in a decrease in their voting power in the company.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$1.10 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
Mesoblast Limited has announced that JPMorgan Chase & Co. and its affiliates have become substantial holders in the company, holding a 5.06% voting power with 64,614,620 ordinary shares. This development indicates a significant investment by JPMorgan, which could influence Mesoblast’s market dynamics and stakeholder interests, highlighting the strategic importance of this financial backing in the company’s future operations.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$1.10 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
Mesoblast Limited has announced that JPMorgan Chase & Co. and its affiliates have ceased to be substantial holders in the company as of June 11, 2025. This change in substantial holding involves various transactions and securities lending agreements managed by JPMorgan’s subsidiaries, impacting the voting securities of Mesoblast Limited. The cessation of JPMorgan’s substantial holding could influence Mesoblast’s shareholder dynamics and market perception.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$1.10 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
Mesoblast Limited has reported progress with the FDA on the accelerated approval pathway for its product Revascor® in treating ischemic chronic heart failure and a label extension for Ryoncil® in adults with steroid-refractory acute graft versus host disease (SR-aGvHD). The company held a Type B meeting with the FDA to discuss a potential Biologics License Application for Revascor® and plans a meeting in July to discuss a pivotal trial for Ryoncil® in adults. Ryoncil® has been commercially available in the U.S. since March 2025, with significant uptake and coverage expansion, indicating strong market acceptance and potential growth in the cellular medicine industry.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$1.10 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
The Vanguard Group has become a substantial holder in Mesoblast Limited, acquiring a 5.004% voting power with 63,941,083 ordinary shares. This significant investment by a major global asset manager could enhance Mesoblast’s market credibility and attract further interest from investors, potentially impacting its stock performance and strategic positioning in the biotechnology sector.
The most recent analyst rating on (AU:MSB) stock is a Hold with a A$2.30 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
Mesoblast Limited has announced that JPMorgan Chase & Co. and its affiliates have become substantial holders in the company, with a 5.06% voting power through various securities holdings and agreements. This development indicates a significant investment by JPMorgan, potentially impacting Mesoblast’s market position and signaling confidence in the company’s future prospects.
The most recent analyst rating on (AU:MSB) stock is a Hold with a A$1.10 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
Mesoblast Limited has announced a substantial holding update, indicating significant voting power and relevant interests held by various entities, including State Street Corporation and its subsidiaries. The update highlights the extensive involvement of institutional investors and financial entities in the company’s shares, which may influence Mesoblast’s market dynamics and stakeholder interests.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$1.10 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
Mesoblast Limited has received a seven-year orphan-drug exclusive approval from the FDA for its product Ryoncil® (remestemcel-L), used in treating steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients. This exclusivity prevents the approval of similar mesenchymal stromal or stem cell products for the same indication during this period. Additionally, Mesoblast holds biologic exclusivity until December 2036, protecting against biosimilar market entry. These exclusivities, combined with Mesoblast’s strong intellectual property portfolio, provide a significant commercial barrier to competitors, reinforcing the company’s market position and offering long-term protection in major markets.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$3.40 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
JPMorgan Chase & Co. and its affiliates have become substantial holders in Mesoblast Limited, acquiring a 5.03% voting power in the company as of May 9, 2025. This development may influence Mesoblast’s market positioning and stakeholder interests, as JPMorgan’s involvement could bring increased financial scrutiny and potential strategic opportunities.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$1.10 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
Mesoblast Limited has announced that JPMorgan Chase & Co. and its affiliates have ceased to be a substantial holder in the company. This change in substantial holding involves various transactions, including securities lending and proprietary trading, which have impacted the voting securities of Mesoblast Limited. The cessation of JPMorgan’s substantial holding may influence the company’s market perception and stakeholder dynamics.
Mesoblast Limited, a company involved in the biotechnology sector, announced a change in substantial holding as State Street Corporation and its subsidiaries ceased to be substantial holders. This change in substantial holding may impact Mesoblast’s shareholder composition and influence its market positioning, as State Street Corporation’s involvement in voting securities has altered.
Mesoblast Limited has announced a new substantial holder, Aware Super Pty Ltd, which has acquired a significant voting power in the company. This change in substantial holding may impact Mesoblast’s strategic decisions and influence its market position, as the new holder has the power to control voting rights and securities disposal.
Mesoblast Limited announced the commercial availability of Ryoncil® (remestemcel-L) for treating children with acute GVHD in the U.S., following FDA approval. The company is expanding its reach with plans to onboard more transplant centers and increase insurance coverage. Additionally, Mesoblast is progressing with its Revascor® and rexlemestrocel-L therapies, with ongoing FDA discussions and trials aimed at addressing chronic heart failure and low back pain, respectively. The company also strengthened its financial position with a successful global private placement and enhanced its board of directors.
Mesoblast Limited announced the appointment of Lyn Cobley as a new director, effective April 29, 2025. Cobley holds 33,000 ordinary shares through Synergy Finance Pty Ltd as trustee for Cobley Superfund. This appointment may influence the company’s strategic direction and stakeholder confidence, given Cobley’s experience and interests in the company.
Mesoblast Limited has appointed Lyn Cobley, a seasoned leader in the financial services industry, to its Board of Directors. This strategic move follows the recent FDA approval of RYONCIL and aims to bolster Mesoblast’s commercialization efforts and expansion into new indications for prevalent diseases. Cobley’s extensive experience in corporate finance and governance is expected to enhance Mesoblast’s strategic leadership as it continues to develop and commercialize its cell therapy products.
Mesoblast Limited has announced a change in the director’s interest, specifically involving Gregory George. The change includes the acquisition of 50,000 American Depositary Shares (ADS) and the expiry of a put option over the same amount. This update reflects ongoing adjustments in the company’s director-level securities holdings, which could influence stakeholder perceptions and the company’s market dynamics.
Mesoblast has successfully expanded the coverage of its FDA-approved therapy, Ryoncil, to over 100 million insured lives in the United States. This expansion includes Medicaid and commercial payers, highlighting the therapy’s growing acceptance and potential impact on treating steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients. The increased coverage is expected to enhance Mesoblast’s market position and provide broader access to its innovative treatment, potentially benefiting stakeholders and patients alike.